Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

This is an interventional treatment trial for Urinary Frequency/Urgency focused on measuring bladder pain, urinary frequency, urinary urgency, mirabegron Read More

Inclusion Criteria:

1. English-speaking women
2. Age: 18 and 89 years
3. Pain related urinary frequency or urgency associated with >70% of voids. With a minimum of 7 pain motivated voids in 24 hours.
4. Bladder capacity: > 300 ml
5. Urinary frequency: 10 or more voids in 24/hours on voiding diary

Exclusion Criteria:

1. Severe Liver disease: Child-Pugh class c
2. Severe Kidney disease: GFR<30
3. Elevated blood pressure > 160/95 (in package insert bp >180/110)
4. Pregnant, will become pregnant, or are nursing during the study
5. History of recurrent urinary tract infection: 3 or more culture proven urinary tract infections in the past 12 months. An active urinary tract infection.
6. Tachycardia: pulse > 100, or any other history of arrhythmia
7. Intense urge: bladder volumes of <150 ml on cystometry
8. Presently on study drug mirabegron; patient must be willing to participate in a 30 day washout period to be eligible for inclusion
9. Medications: metoprolol, desipramine, digoxin, propafenone, thioridazine, flecainide, warfarin
10. Pain medications: no dose changes in narcotic or non-steroidal medications while on study. Patient must be on a stable medication dose for at least 30 days prior to the screening visit.
11. Neurogenic pain medications such as gabapentin or amitriptyline: no dose changes while on study. Patient must be on a stable medication dose for at least 30 days prior to the screening visit.
12. Anticholinergic medications for incontinence: no dose changes while on study. Patient must be on a stable medication dose for at least 30 days prior to the screening visit.